Literature DB >> 26077165

Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility.

Haijin Zhao1, Rui Li1, Yanhua Lv1, Hangming Dong1, Lihong Yao1, Yue Wu1, Guanhua Xiao1, Shaoxi Cai1.   

Abstract

INTRODUCTION: Fractional exhaled nitric oxide (FeNO) has been used as a marker of airway inflammation. Airway caliber is related to the level of FeNO in asthmatics.
OBJECTIVES: This study aimed to investigate whether airway obstruction could interfere with real FENO levels and if different FeNO changes after albuterol inhalation could assist in distinguishing asthma from chronic obstructive pulmonary disease (COPD).
METHODS: FeNO and spirometry measurements were performed before and after albuterol inhalation in the following three patient groups: 30 steroid-naive asthmatics, 25 asthmatics inhaling corticosteroids/long-acting β(2)-adrenergic agonists for at least 1 month and 20 COPD patients. Bronchodilator test (BDT) results were positive in all patients enrolled. The correlations among FeNO levels, pulmonary function and sputum eosinophil counts were analyzed.
RESULTS: FeNO increased significantly after albuterol inhalation in steroid-naive asthmatics but not in ICS-treated asthmatics or COPD patients. The FeNO levels demonstrated no significant correlation with spirometry results or sputum eosinophil counts before or after inhaling bronchodilator in all three groups. Both the levels of FeNO and changes in FENO after albuterol inhalation in steroid-naive asthma patients were higher than those in ICS-treated asthmatics and COPD patients (P < 0.001). The differences remained after proper adjustment for confounding factors (gender, age, smoking pack-years, ICS-treated and pulmonary function index).
CONCLUSIONS: Our results support the role of FeNO in differentiating asthmatics from COPD patients with positive BDT. FeNO detection after albuterol inhalation should be encouraged in steroid-naive asthma patients with airway obstruction.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  airway calibers - asthma - COPD - fractional exhaled nitric oxide - positive bronchodilator test

Mesh:

Substances:

Year:  2015        PMID: 26077165     DOI: 10.1111/crj.12340

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  5 in total

1.  It is time to end our love affair with short-acting β2-agonists in asthma.

Authors:  Michael G Crooks; Shoaib Faruqi
Journal:  ERJ Open Res       Date:  2022-10-17

Review 2.  [Research progress in relationship between fractional exhaled nitric oxide and asthma in children].

Authors:  Jing Zeng; Wei Liao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-09

3.  Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting.

Authors:  Guanghui Zhou; Xianhua Gui; Ruhua Chen; Xingli Fu; Xiuhai Ji; Hui Ding
Journal:  Clinics (Sao Paulo)       Date:  2019-06-27       Impact factor: 2.365

4.  A call to action for improving clinical outcomes in patients with asthma.

Authors:  Andrew McIvor; Alan Kaplan
Journal:  NPJ Prim Care Respir Med       Date:  2020-12-04       Impact factor: 2.871

5.  Effect of Inhaled β2-Agonist on Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease.

Authors:  Mostafa Amer; Jan Cowan; Andrew Gray; Ben Brockway; Jack Dummer
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.